Positive News SentimentPositive NewsNASDAQ:TERN Terns Pharmaceuticals (TERN) Stock Price, News & Analysis $3.14 +0.08 (+2.45%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Terns Pharmaceuticals Stock (NASDAQ:TERN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Terns Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.06▼$3.1750-Day Range$2.00▼$3.5652-Week Range$1.87▼$11.40Volume230,995 shsAverage Volume1.53 million shsMarket Capitalization$273.80 millionP/E RatioN/ADividend YieldN/APrice Target$15.63Consensus RatingModerate Buy Company OverviewTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Read More… Terns Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreTERN MarketRank™: Terns Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 178th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingTerns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTerns Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Terns Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Terns Pharmaceuticals is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Terns Pharmaceuticals is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTerns Pharmaceuticals has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Terns Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.22% of the float of Terns Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTerns Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Terns Pharmaceuticals has recently increased by 0.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTerns Pharmaceuticals does not currently pay a dividend.Dividend GrowthTerns Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-0.95 Percentage of Shares Shorted8.22% of the float of Terns Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTerns Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Terns Pharmaceuticals has recently increased by 0.74%, indicating that investor sentiment is decreasing. News and Social Media4.3 / 5News Sentiment1.65 News SentimentTerns Pharmaceuticals has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Terns Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest3 people have searched for TERN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows6 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Terns Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,370.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Terns Pharmaceuticals is held by insiders.Percentage Held by Institutions98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Terns Pharmaceuticals' insider trading history. Receive TERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TERN Stock News HeadlinesTerns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potentialMay 27 at 9:15 PM | investing.comTerns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701May 14, 2025 | globenewswire.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 29, 2025 | Brownstone Research (Ad)Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | insidermonkey.comTerns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 8, 2025 | globenewswire.comTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)May 2, 2025 | globenewswire.comTerns Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comDoes Terns Pharmaceuticals Have A Long Cash Runway?April 23, 2025 | finance.yahoo.comSee More Headlines TERN Stock Analysis - Frequently Asked Questions How have TERN shares performed this year? Terns Pharmaceuticals' stock was trading at $5.54 on January 1st, 2025. Since then, TERN shares have decreased by 43.4% and is now trading at $3.1350. View the best growth stocks for 2025 here. How were Terns Pharmaceuticals' earnings last quarter? Terns Pharmaceuticals, Inc. (NASDAQ:TERN) posted its earnings results on Thursday, May, 8th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03. When did Terns Pharmaceuticals IPO? Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO. Who are Terns Pharmaceuticals' major shareholders? Terns Pharmaceuticals' top institutional shareholders include Nuveen LLC (1.61%), Parkman Healthcare Partners LLC (1.10%), Driehaus Capital Management LLC (0.87%) and Walleye Capital LLC (0.68%). Insiders that own company stock include Orbimed Advisors Llc, Biosciences Fund V LP Lav, Vivo Opportunity, Llc, Mark J Vignola, Emil Kuriakose, Amy L Burroughs, Melita Sun Jung and Jill M Quigley. View institutional ownership trends. How do I buy shares of Terns Pharmaceuticals? Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Terns Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX). Company Calendar Last Earnings5/08/2025Today5/29/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TERN CIK1831363 Webwww.ternspharma.com Phone650-525-5535FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$15.63 High Stock Price Target$20.00 Low Stock Price Target$7.50 Potential Upside/Downside+398.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.76% Return on Assets-31.33% Debt Debt-to-Equity RatioN/A Current Ratio32.99 Quick Ratio32.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book0.76Miscellaneous Outstanding Shares87,337,000Free Float72,113,000Market Cap$273.80 million OptionableNot Optionable Beta-0.16 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TERN) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.